PH12021550883A1 - Crystalline salts of a plasma kallikrein inhibitor - Google Patents

Crystalline salts of a plasma kallikrein inhibitor

Info

Publication number
PH12021550883A1
PH12021550883A1 PH12021550883A PH12021550883A PH12021550883A1 PH 12021550883 A1 PH12021550883 A1 PH 12021550883A1 PH 12021550883 A PH12021550883 A PH 12021550883A PH 12021550883 A PH12021550883 A PH 12021550883A PH 12021550883 A1 PH12021550883 A1 PH 12021550883A1
Authority
PH
Philippines
Prior art keywords
crystalline salts
plasma kallikrein
kallikrein inhibitor
crystalline
salts
Prior art date
Application number
PH12021550883A
Other languages
English (en)
Inventor
Yahya El-Kattan
Yarlagadda S Babu
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70457981&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12021550883(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of PH12021550883A1 publication Critical patent/PH12021550883A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PH12021550883A 2018-11-02 2021-04-21 Crystalline salts of a plasma kallikrein inhibitor PH12021550883A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862754983P 2018-11-02 2018-11-02
PCT/US2019/059385 WO2020092898A1 (en) 2018-11-02 2019-11-01 Crystalline salts of a plasma kallikrein inhibitor

Publications (1)

Publication Number Publication Date
PH12021550883A1 true PH12021550883A1 (en) 2022-02-21

Family

ID=70457981

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12021550883A PH12021550883A1 (en) 2018-11-02 2021-04-21 Crystalline salts of a plasma kallikrein inhibitor

Country Status (22)

Country Link
US (11) US10662160B1 (cg-RX-API-DMAC7.html)
EP (1) EP3873463A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022505670A (cg-RX-API-DMAC7.html)
KR (1) KR102810837B1 (cg-RX-API-DMAC7.html)
CN (1) CN112969458A (cg-RX-API-DMAC7.html)
AR (1) AR116951A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019374115B8 (cg-RX-API-DMAC7.html)
BR (1) BR112021008249A2 (cg-RX-API-DMAC7.html)
CA (1) CA3117123A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001094A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021007172A2 (cg-RX-API-DMAC7.html)
EA (1) EA202191192A1 (cg-RX-API-DMAC7.html)
IL (2) IL322896A (cg-RX-API-DMAC7.html)
MA (1) MA54087A (cg-RX-API-DMAC7.html)
MX (1) MX2021004917A (cg-RX-API-DMAC7.html)
PE (1) PE20211280A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021550883A1 (cg-RX-API-DMAC7.html)
PY (1) PY1991831A (cg-RX-API-DMAC7.html)
SG (1) SG11202103804TA (cg-RX-API-DMAC7.html)
TW (1) TW202031255A (cg-RX-API-DMAC7.html)
UY (1) UY38438A (cg-RX-API-DMAC7.html)
WO (1) WO2020092898A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20221373T1 (hr) 2014-03-07 2023-01-06 Biocryst Pharmaceuticals, Inc. Supstituirani pirazoli kao inhibitori kalikreina u ljudskoj plazmi
UY38438A (es) 2018-11-02 2020-05-29 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática
WO2021025969A1 (en) * 2019-08-02 2021-02-11 Teva Pharmaceuticals International Gmbh Solid state forms of berotralstat
CN116375648A (zh) * 2023-03-22 2023-07-04 苏州农平科技发展有限公司 贝罗司他中间体的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) * 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
EP1828187A2 (en) 2004-12-15 2007-09-05 Brystol-Myers Squibb Company Crystalline forms of a factor xa inhibitor
CN101495468A (zh) * 2006-07-31 2009-07-29 艾克提弗赛特制药股份有限公司 血浆激肽释放酶抑制剂
EP2051707B1 (en) 2006-07-31 2013-07-17 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
CN102892763B (zh) * 2010-05-19 2016-03-09 桑多斯股份公司 泊沙康唑及泊沙康唑中间体的纯化
JP5808818B2 (ja) 2010-11-25 2015-11-10 ラツィオファーム・ゲーエムベーハー アファチニブの新規塩及び多形形態
GB201212081D0 (en) * 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
HRP20221373T1 (hr) * 2014-03-07 2023-01-06 Biocryst Pharmaceuticals, Inc. Supstituirani pirazoli kao inhibitori kalikreina u ljudskoj plazmi
FI4019022T3 (fi) 2015-10-01 2024-04-19 Biocryst Pharm Inc Ihmisen plasman kallikreiinin estäjiä
UY38438A (es) 2018-11-02 2020-05-29 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática
EP4010320A4 (en) 2019-08-06 2023-08-16 Biocryst Pharmaceuticals, Inc. Process-scale synthesis of a plasma kallikrein inhibitor

Also Published As

Publication number Publication date
US12552750B2 (en) 2026-02-17
US11618733B2 (en) 2023-04-04
BR112021008249A2 (pt) 2021-08-03
MX2021004917A (es) 2021-06-18
KR102810837B1 (ko) 2025-05-20
TW202031255A (zh) 2020-09-01
US12545647B2 (en) 2026-02-10
IL282454A (en) 2021-06-30
US20220204454A1 (en) 2022-06-30
AU2019374115A1 (en) 2021-06-03
US20250388549A1 (en) 2025-12-25
CL2021001094A1 (es) 2021-10-15
JP2024109860A (ja) 2024-08-14
AU2019374115B1 (en) 2025-07-17
US20250388545A1 (en) 2025-12-25
US12545646B2 (en) 2026-02-10
US20240109844A1 (en) 2024-04-04
US10662160B1 (en) 2020-05-26
UY38438A (es) 2020-05-29
CO2021007172A2 (es) 2021-06-10
US20250388547A1 (en) 2025-12-25
US20250376447A1 (en) 2025-12-11
EP3873463A4 (en) 2022-06-22
KR20210087037A (ko) 2021-07-09
IL322896A (en) 2025-10-01
SG11202103804TA (en) 2021-05-28
US20250376448A1 (en) 2025-12-11
EA202191192A1 (ru) 2021-09-23
US11117867B2 (en) 2021-09-14
EP3873463A1 (en) 2021-09-08
US12590068B2 (en) 2026-03-31
US20200140389A1 (en) 2020-05-07
WO2020092898A1 (en) 2020-05-07
MA54087A (fr) 2022-02-09
PE20211280A1 (es) 2021-07-19
US12344585B2 (en) 2025-07-01
US20250388546A1 (en) 2025-12-25
CA3117123A1 (en) 2020-05-07
US20250388548A1 (en) 2025-12-25
PY1991831A (es) 2020-07-03
JP2022505670A (ja) 2022-01-14
US20200308118A1 (en) 2020-10-01
CN112969458A (zh) 2021-06-15
AR116951A1 (es) 2021-06-30
US12590069B2 (en) 2026-03-31
US12545645B2 (en) 2026-02-10
AU2019374115B8 (en) 2025-08-07

Similar Documents

Publication Publication Date Title
ZA202202097B (en) Amino pyrimidine ssao inhibitors
ZA202206923B (en) New methylquinazolinone derivatives
NZ763551A (en) Compounds useful for inhibiting cdk7
EA202193015A1 (ru) Ингибиторы cdk
SA520411524B1 (ar) مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها
AU2018271990A1 (en) Covalent inhibitors of KRAS
MX2020007797A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
CA2983481A1 (en) Janus kinase inhibitor
MX2021005075A (es) Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion.
NZ762034A (en) Human plasma kallikrein inhibitors
MX2020005484A (es) Formas solidas de un inhibidor de calicreina en plasma y sales del mismo.
PH12020550253A1 (en) Bicyclic compounds for use as rip1 kinase inhibitors
SA519402288B1 (ar) مركب بيريميدين واستخداماته الصيدلانية
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
MX2021007247A (es) Derivados de rapamicina.
EP4339192A3 (en) Compounds and compositions for the treatment of cancer
WO2018125880A8 (en) Nrf2 activator
EA202191192A1 (ru) Кристаллические соли ингибитора плазменного калликреина
MY193239A (en) Novel b-lactamase inhibitors
PH12022551403A1 (en) Process and intermediate for the preparation of oxetan-2-ylmethanamine.
MX379576B (es) Derivados de azetidina
WO2021102359A3 (en) Taspase1 inhibitors and uses thereof
MX2020005168A (es) Formas de dosificacion que contienen un inhibidor calicreina de plasma.
PH12021550323A1 (en) Dendrimer formulations
ZA201904033B (en) Pharmaceutical compounds